Clopidogrel Versus Dual-Antiplatelet Therapy for Long-Term Maintenance After Coronary Stenting in Ischemic and Bleeding Birisk Patients With Acute Coronary Syndromes and Diabetes: A Prespecified Subgroup Analysis of the OPT-BIRISK Trial.

In 30 seconds

This prespecified subgroup analysis of the OPT-BIRISK trial evaluated the effects of clopidogrel monotherapy versus dual-antiplatelet therapy in birisk patients with acute coronary syndrome and diabetes. The study found that clopidogrel monotherapy reduced Bleeding Academic Research Consortium type 2, 3, or 5 bleeding to 2.1% compared to 3.2% with dual therapy, without increasing major adverse cardiac and cerebral events.

Key findings

• Clopidogrel monotherapy reduced bleeding events to 2.1% compared to 3.2% with dual therapy (HR, 0.66).
• No increase in major adverse cardiac and cerebral events was observed (2.9% vs 3.6%; HR, 0.79).
• Results were consistent in patients with and without diabetes.

Why it matters

The findings suggest that clopidogrel monotherapy may be a safer long-term maintenance strategy for birisk patients with acute coronary syndrome, particularly in reducing bleeding risks without compromising ischemic outcomes.